Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nirmatrelvir/ritonavir in immunocompromised nonhospitalized patients with symptomatic COVID-19
2022-001362-35Phase 2Active
- Sponsor
- Pfizer
- Start
- Jul 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Nirmatrelvir and ritonavir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Pfizer. Primary endpoint: Proportion of participants with sustained nasopharyngeal swab SARS-CoV-2 RNA below lower limit of quantification from end of treatment through Day 44. Started Jul 2022; status: active.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-001362-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001362-35.